TY - JOUR
T1 - Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients
AU - Harris, Anthony D.
AU - Smith, David
AU - Johnson, Judith A.
AU - Bradham, Douglas D.
AU - Roghmann, Mary Claire
N1 - Funding Information:
Financial support: Unrestricted grants from Merck, Wyeth-Ayerst, and Bayer. The companies had no involvement in the study design, data analysis, or writing or editing of the manuscript.
PY - 2002/2/1
Y1 - 2002/2/1
N2 - Risk factors for the nosocomial recovery of imipenem-resistant Pseudomonas aeruginosa (IRPA) were determined. A case-control study design was used for the comparison of 2 groups of case patients with control patients. The first group of case patients had nosocomial isolation of IRPA, and the second group had imipenem-susceptible P. aeruginosa (ISPA). Control patients were selected from the same medical or surgical services from which case patients were receiving care when isolation of IRPA occurred. Risk factors analyzed included antimicrobials used, comorbid conditions, and demographic variables. IRPA was recovered from 120 patients, and ISPA from 662 patients. Imipenem (odds ratio [OR], 4.96), piperacillin-tazobactam (OR, 2.39), vancomycin (OR, 1.80), and aminoglycosides (OR, 2.19) were associated with isolation of IRPA. Vancomycin (OR, 1.64), ampicillin-sulbactam (OR, 2.00), and second-generation cephalosporins (OR, 2.00) were associated with isolation of ISPA. Antibiotics associated with ISPA are different from antibiotics associated with IRPA. The OR for imipenem as a risk factor for IRPA is less than that reported from studies in which control group selection was suboptimal.
AB - Risk factors for the nosocomial recovery of imipenem-resistant Pseudomonas aeruginosa (IRPA) were determined. A case-control study design was used for the comparison of 2 groups of case patients with control patients. The first group of case patients had nosocomial isolation of IRPA, and the second group had imipenem-susceptible P. aeruginosa (ISPA). Control patients were selected from the same medical or surgical services from which case patients were receiving care when isolation of IRPA occurred. Risk factors analyzed included antimicrobials used, comorbid conditions, and demographic variables. IRPA was recovered from 120 patients, and ISPA from 662 patients. Imipenem (odds ratio [OR], 4.96), piperacillin-tazobactam (OR, 2.39), vancomycin (OR, 1.80), and aminoglycosides (OR, 2.19) were associated with isolation of IRPA. Vancomycin (OR, 1.64), ampicillin-sulbactam (OR, 2.00), and second-generation cephalosporins (OR, 2.00) were associated with isolation of ISPA. Antibiotics associated with ISPA are different from antibiotics associated with IRPA. The OR for imipenem as a risk factor for IRPA is less than that reported from studies in which control group selection was suboptimal.
UR - http://www.scopus.com/inward/record.url?scp=0036467142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036467142&partnerID=8YFLogxK
U2 - 10.1086/338237
DO - 10.1086/338237
M3 - Article
C2 - 11774081
AN - SCOPUS:0036467142
SN - 1058-4838
VL - 34
SP - 340
EP - 345
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -